These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 15389811

  • 1. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H, Messing EM, Chang C.
    Prostate; 2004 Dec 01; 61(4):332-53. PubMed ID: 15389811
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F.
    Bull Cancer; 2006 Sep 01; 93(9):949-58. PubMed ID: 16980238
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN, Schröder FH.
    BJU Int; 2009 Aug 01; 104(4):438-48. PubMed ID: 19558559
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 01; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 15. Maximal androgen blockade for advanced prostate cancer.
    Klotz L.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 01; 22(2):331-40. PubMed ID: 18471790
    [Abstract] [Full Text] [Related]

  • 16. Androgen axis in prostate cancer.
    Culig Z, Bartsch G.
    J Cell Biochem; 2006 Oct 01; 99(2):373-81. PubMed ID: 16598769
    [Abstract] [Full Text] [Related]

  • 17. Hormonal ablation therapy for metastatic prostatic carcinoma: a review.
    Leewansangtong S, Soontrapa S.
    J Med Assoc Thai; 1999 Feb 01; 82(2):192-205. PubMed ID: 10087729
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY.
    J Pathol; 2005 Jun 01; 206(2):205-13. PubMed ID: 15818594
    [Abstract] [Full Text] [Related]

  • 20. Maximal androgen blockade versus total androgen suppression.
    Dumez H, Van Poppel H, Baert L, Paridaens R.
    Acta Urol Belg; 1997 Mar 01; 65(1):49-54. PubMed ID: 9175283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.